Relay Therapeutics (NASDAQ:RLAY) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $20.4, a high estimate of $25.00, and a low estimate of $15.00. Observing a downward trend, the current average is 8.93% lower than the prior average price target of $22.40. Diving in…